Questions to Ask About Chronic Kidney Disease

Questions to ask about chronic kidney disease fall into three distinct categories — understanding the diagnosis and what it means, managing the condition day-to-day, and planning for what comes next — and having the right questions in each category determines how well a patient understands their own condition and how actively they can participate in the management decisions that will shape their health trajectory. CKD is diagnosed at a moment when most patients have little experience with kidney disease, a limited understanding of what eGFR and staging actually mean, and no framework for the monitoring and management process they are about to enter. The questions a newly diagnosed patient asks in the first appointment, and the questions a patient with established CKD asks at each subsequent visit, determine whether they leave with clarity and a plan or leave with information they don’t know how to use. This article provides a structured question framework for each type of CKD conversation — the diagnostic conversation, the monitoring conversation at established appointments, the dietary and lifestyle conversation, and the planning conversation about progression and kidney replacement therapy. For the broader appointment preparation structure that these questions fit into, see the companion article on the doctor visit checklist for kidney health. For understanding what the lab values being discussed mean, see kidney function tests: a simple guide and the article on what is eGFR.

Diagnostic Questions: What to Ask When First Diagnosed With CKD

The first appointment after a CKD diagnosis establishes the patient’s understanding of their condition and the management framework for everything that follows. Patients who leave this appointment with a clear understanding of what CKD means, what stage they are at, what caused it, and what the monitoring plan is will be better equipped to manage the condition than patients who leave with a diagnosis they don’t fully understand. The following questions are specifically relevant to the diagnostic conversation. “What stage of CKD do I have, and what does my eGFR mean?” CKD is staged using eGFR (estimated glomerular filtration rate) and proteinuria. Stages 1–2 indicate kidney damage with preserved or mildly reduced function (eGFR ≥60); stages 3a–3b indicate moderate reduction in function (eGFR 30–59); stage 4 indicates severe reduction (eGFR 15–29); stage 5 indicates kidney failure (eGFR <15). Understanding which stage applies and what the eGFR number means in practical terms — what percentage of normal kidney function it represents — gives patients a concrete anchor for understanding their condition. “What caused my CKD?” The most common causes of CKD are diabetes (diabetic nephropathy), high blood pressure (hypertensive nephrosclerosis), and glomerulonephritis. Identifying the underlying cause matters because treatment of the underlying cause is a primary mechanism for slowing CKD progression — blood sugar control in diabetic nephropathy, blood pressure control in hypertensive kidney disease, immunosuppression in certain forms of glomerulonephritis. “What is the difference between CKD that is stable versus CKD that is progressing?” Not all CKD progresses to kidney failure. Many patients, particularly those with stage 3 CKD that is detected and managed early, maintain stable kidney function for years or decades. Understanding what “stable” means in measurable terms — eGFR variation within normal measurement variability, stable or decreasing proteinuria — helps patients understand what they are monitoring for. “What is the monitoring schedule, and what does each lab test measure?” The standard CKD monitoring schedule — how often eGFR, creatinine, ACR, and metabolic panel should be checked — depends on CKD stage and the rate of prior progression. Understanding what each monitoring test measures and why it is checked at the specified frequency allows patients to engage with the monitoring as an active participant rather than a passive recipient of periodic blood draws. The NIDDK overview of CKD stages and monitoring, at the NIDDK CKD information page, provides accessible explanations of staging and monitoring that complement the clinical conversation. “Are there other specialists I should see?” CKD often involves co-management by a nephrologist with cardiologists (cardiovascular disease is the leading cause of death in CKD patients), endocrinologists (for diabetes management), and dietitians with CKD-specific expertise. Understanding at the first appointment whether specialist coordination is part of the care plan prevents the situation of discovering months later that a referral would have been appropriate and wasn’t made.

Monitoring Questions: What to Ask at Every Established CKD Appointment

At established CKD appointments — appointments where the diagnosis is known and the management is ongoing — the relevant questions shift from “what is this condition?” to “how is the condition tracking and what needs to be adjusted?” The following questions form the core monitoring conversation that should occur at every nephrology appointment regardless of the specific clinical focus at that visit. “What is my eGFR today, and how does it compare to my prior readings?” This is the foundational monitoring question. A single eGFR has limited meaning; the trend across multiple readings is what determines whether CKD is stable, declining slowly, or declining more rapidly than expected. A well-managed CKD patient knows their current eGFR and its trajectory. “What is my current creatinine, and what was it last time?” Creatinine and eGFR are related — creatinine rises as eGFR falls — but tracking both provides cross-validation. Some patients also find it easier to track creatinine as a concrete number than eGFR as a calculated estimate. “Has my proteinuria changed?” Proteinuria — measured as urine albumin-to-creatinine ratio (ACR) or urine protein — is one of the strongest predictors of CKD progression and cardiovascular risk. An increase in ACR from the prior reading is a clinically significant finding regardless of whether the absolute value crosses a category threshold. For patients who want a detailed explanation of what ACR means and how to interpret changes over time, the article on albumin-to-creatinine ratio: what adults should know provides the full clinical context. “Is my blood pressure at target?” Blood pressure control is one of the most evidence-based interventions for slowing CKD progression. The target is typically below 130/80 mmHg in CKD patients, with tighter targets in patients with significant proteinuria. Bringing the home blood pressure log and asking specifically whether the average readings over the past four to eight weeks meet the target provides a more complete answer than relying on the office blood pressure reading alone. “Are any of my electrolytes or other metabolic values concerning?” CKD disrupts electrolyte and metabolic balance. Potassium, bicarbonate, phosphorus, calcium, and hemoglobin are all affected by declining kidney function and require monitoring. Asking whether any values are trending in a direction that warrants dietary or medication adjustment ensures that emerging abnormalities are identified early rather than at the point when they require urgent intervention. “Does my current medication list need adjustment for my current kidney function?” Many medications require dose adjustment as eGFR declines. Asking this question at each visit prompts a systematic review of the current medication list against the current eGFR — a review that might otherwise be missed between appointments when medications have been stable for months. The KDIGO clinical practice guidelines on CKD evaluation and management, at the KDIGO CKD guidelines page, provide the evidence base for the monitoring and treatment targets that the care team is working toward at each appointment.

Diet and Lifestyle Questions: What to Ask About Daily Management

Dietary and lifestyle management in CKD is stage-specific, cause-specific, and individual — what applies to a stage 3a patient with diabetic nephropathy and a potassium of 5.1 is different from what applies to a stage 4 patient with IgA nephropathy and a potassium of 4.2. The questions in this section help patients understand the specific dietary and lifestyle recommendations that apply to their current situation rather than applying generic CKD dietary guidance that may not be appropriate for their individual clinical profile. “What are my current dietary targets for sodium, potassium, phosphorus, and protein?” CKD dietary management typically involves sodium restriction (≤2,000–2,300 mg/day for blood pressure management), potassium restriction (when serum potassium is elevated), phosphorus restriction (when serum phosphorus is elevated, generally stage 3b and beyond), and protein intake consideration (which has a complex evidence base in CKD — neither very low protein nor very high protein is generally recommended). These targets are stage-specific and individual — asking for the specific current targets rather than applying generic online guidance prevents both unnecessary restriction and inadequate management. “Do I need to see a renal dietitian, and is one available through this practice?” A renal dietitian with CKD-specific expertise provides individualized dietary guidance that accounts for the patient’s current lab values, medication list, food preferences, and CKD stage. Not every CKD patient needs an urgent renal dietitian referral, but patients with stage 3b or later, with elevated potassium or phosphorus, or with diabetes and CKD typically benefit substantially from individualized dietary guidance that goes beyond what can be covered in a nephrology appointment. “What exercise or physical activity level is appropriate for my CKD stage?” Physical activity has documented benefits in CKD — improved cardiovascular outcomes, better blood pressure control, improved quality of life — but the appropriate type and intensity depends on the individual patient’s cardiovascular status, anemia severity, bone health, and dialysis status if applicable. Asking for specific guidance rather than applying general exercise recommendations ensures that the activity level is appropriate for the specific clinical context. “Are there any supplements or herbal products I should avoid with CKD?” Many common supplements — including certain herbal products, high-dose vitamin C, potassium-containing supplements, phosphorus-containing supplements, and nephrotoxic herbs including aristolochic acid-containing products — are contraindicated or require caution in CKD. This question should prompt a review of the current supplement list against the current CKD stage and metabolic profile. For a detailed treatment of supplement safety in CKD, the article on supplement safety for people with kidney disease provides a comprehensive evaluation framework. “Are there any OTC medications I should be careful about?” NSAIDs (ibuprofen, naproxen, aspirin at analgesic doses) are nephrotoxic and should generally be avoided in CKD or used only at the lowest effective dose for the shortest possible duration. Certain contrast agents used in imaging studies also carry nephrotoxic risk in CKD patients. Asking about OTC medication cautions at each appointment ensures that the care team is aware of what the patient is taking and that the patient understands the risks of commonly available medications. The NKF patient resources on living with kidney disease, at the NKF CKD resource page, provide accessible guidance on dietary and lifestyle management that complements the clinical recommendations.

Progression and Planning Questions: What to Ask About the Future

As CKD advances through the stages, and particularly as eGFR declines below 30 (stage 4), questions about the longer-term trajectory and kidney replacement therapy options become increasingly important. These are the questions that patients often avoid asking because they are uncomfortable to face — but they are the questions that, answered early, allow patients to make informed decisions about treatment options rather than being forced into emergency decisions when kidney function declines rapidly. “At my current rate of progression, when might I need kidney replacement therapy?” This question has a probabilistic rather than certain answer — CKD progression rate varies and can be modified by management — but the care team can typically provide an estimate based on the current eGFR, the recent eGFR trajectory, and the rate of proteinuria. Understanding whether the estimated timeframe is years away or potentially approaching within 12–24 months determines the urgency of planning conversations. “What are my kidney replacement therapy options, and when should I start learning about them?” The three main kidney replacement therapy options are hemodialysis, peritoneal dialysis, and kidney transplantation — including living donor transplantation, which can be pursued before dialysis is needed (preemptive transplantation). Each option has different clinical requirements, lifestyle implications, and planning lead times. Kidney transplantation typically requires 6–24 months on a waiting list (or the identification of a living donor), and dialysis access creation for hemodialysis requires months of healing time. Learning about options early enough to make an informed choice — rather than defaulting to whichever option is most immediately available when kidney function declines — is one of the most important long-term management actions a CKD patient can take. “When should I be referred to a transplant center?” Transplant evaluation can begin when eGFR falls below 20 mL/min/1.73m² at most centers, and listing may occur at eGFR ≤20. Waiting until the patient is already dialysis-dependent to initiate a transplant evaluation is a common but preventable delay. For patients who may be transplant candidates, asking about referral timing at each appointment once eGFR approaches 25–30 ensures that the referral happens at the optimal time rather than being deferred. “What should I do if my kidney function declines more rapidly than expected between appointments?” Identifying in advance the specific triggers — a particular eGFR decline, a specific symptom, a lab value reaching a defined threshold — that should prompt an earlier-than-scheduled appointment or a direct call to the practice ensures that acute changes are recognized and acted on promptly. “Is there anything being developed in CKD treatment that might be relevant to my situation?” SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) have demonstrated significant kidney-protective effects in clinical trials and are now standard of care in many CKD patients, particularly those with diabetes and albuminuria. The treatment landscape for CKD has changed substantially in the last five years, and asking about emerging or recently approved treatments that might apply to the current clinical situation ensures that evidence-based options are not missed. The StatPearls clinical reference on CKD management, at the StatPearls CKD management reference, provides the clinical framework for current evidence-based CKD treatment. For patients who want to build the full management infrastructure — home monitoring, appointment preparation, medication management, long-term planning — around the question framework provided here, the article on long-term kidney care plan provides the organizing structure. The home monitoring that feeds data into the monitoring questions above is covered in home kidney health monitoring: what to track, and the appointment preparation context for using these questions effectively is in the doctor visit checklist for kidney health.

Sources: NIDDK CKD · National Kidney Foundation · KDIGO CKD Guidelines · StatPearls: CKD Management

How to Use These Questions Effectively in the Appointment

Having a list of questions is a starting point, not a complete strategy. The way questions are asked, framed, and followed up within the appointment determines whether they produce useful clinical responses or general reassurances that don’t advance the patient’s understanding. Several practices improve the quality of the answers a patient receives from a well-prepared question list. Ask about specific numbers, not general status: “Is my eGFR of 41 stable compared to where it was six months ago?” produces a specific answer about the magnitude and clinical significance of the change. “Is my kidney disease getting worse?” produces a response that may be more reassuring than informative. CKD care teams are trained to interpret specific data; framing questions around specific values allows them to provide specific clinical context. Ask about next steps, not just current status: after any lab result is discussed, the follow-up question “does this change anything about my management?” converts a data update into an actionable response. A potassium of 5.2 may be within the acceptable range for a patient on a specific medication — or it may prompt a dietary restriction recommendation, a dose adjustment, or an additional monitoring check. The clinical significance of any single result depends on the individual patient’s context; asking about the “so what” brings that context into the conversation. Prioritize the most important questions first: nephrology appointments typically follow a structured review sequence covering labs, blood pressure, medications, and symptoms. Important patient questions that are saved for the end of a 20-minute appointment may receive less thorough attention than they would at the beginning. Mentioning the most pressing concern early — “I wanted to ask specifically about my eGFR drop before we finish today” — ensures the key question is addressed before time pressure constrains the response. Ask for written or portal documentation of key decisions: medication changes, referrals, new targets, and follow-up timelines are all legitimately complex to remember accurately from a single appointment. Most electronic health record systems allow care teams to add action items or send after-visit summaries through the patient portal. Asking “can you add the medication change to my after-visit summary?” ensures the documentation is available when implementing the plan at home. Follow up between appointments when needed: certain questions cannot be fully answered at an appointment because the answer depends on lab results that aren’t back yet, a referral response that takes time, or a clinical situation that needs to be monitored over time before a decision is made. The NIDDK guidance on working with the care team in CKD, at the NIDDK CKD management page, identifies specific situations where patients should contact the care team between appointments rather than waiting for the next scheduled visit — including symptoms that suggest acute kidney injury, significant blood pressure changes, or new medication side effects. Understanding which questions have timed answers that require follow-up versus which questions can wait until the next appointment allows patients to manage the follow-up process effectively. Repeat back and confirm understanding: after any explanation that involves new information — a new medication, a changed target, a referral — repeating the key details back to the care team confirms understanding and provides an opportunity to catch any miscommunication before leaving the appointment. “So I’m reducing my protein intake to 0.8 grams per kilogram per day, which for my weight is about 56 grams of protein per day — is that right?” is a confirmation that takes 15 seconds and prevents an entire management cycle based on a misremembered number.

Questions for Specific CKD Scenarios: High Proteinuria, Anemia, and Mineral Metabolism

Beyond the core monitoring questions, certain clinical situations that are common in CKD warrant their own specific question framework. Patients who are managing one or more of these complications benefit from asking targeted questions at each appointment where the relevant values are reviewed. Questions for high proteinuria (ACR >300 mg/g or urine protein >0.5 g/day): “Is my proteinuria responding to the current RAAS blocker dose?” — ACE inhibitors and ARBs reduce proteinuria and are standard of care; the dose should be optimized to the maximum tolerated. “Is my blood pressure at the tighter target appropriate for high proteinuria?” — guidelines recommend a target below 130/80 for CKD patients with proteinuria, which may be tighter than the general CKD blood pressure target. “Are there any additional agents being considered for proteinuria reduction?” — newer agents including SGLT2 inhibitors and finerenone have demonstrated proteinuria-reducing effects and may be appropriate. Questions for anemia of CKD: “What is my current hemoglobin and what is the target?” — anemia of CKD is treated to a hemoglobin target (typically 10–11.5 g/dL) with erythropoiesis-stimulating agents or iron supplementation; the target range is not the same as the normal hemoglobin range. “Is my ferritin and transferrin saturation at the target needed for ESA therapy?” — iron deficiency limits the response to erythropoiesis-stimulating agents; adequate iron stores are required for effective anemia treatment. “Is my current anemia treatment affecting my symptoms?” — fatigue, dyspnea on exertion, and reduced exercise tolerance are the primary symptoms of anemia of CKD; tracking whether symptoms improve with treatment provides useful clinical information that lab values alone don’t capture. Questions for mineral and bone metabolism (secondary hyperparathyroidism): “What are my current phosphorus, calcium, and PTH levels?” — these three values are the primary markers of mineral metabolism status in CKD and are managed together. “Does my phosphorus level suggest I need a phosphate binder?” — phosphate binders are prescribed to reduce dietary phosphate absorption when serum phosphorus is consistently elevated. “Should I be taking an active vitamin D supplement?” — active vitamin D (calcitriol or analogues) is prescribed in CKD when PTH is elevated, because CKD impairs the kidney’s ability to activate vitamin D. The distinction between active vitamin D (prescription, for PTH management) and cholecalciferol (OTC, for vitamin D deficiency) is clinically important and a question worth asking specifically if vitamin D supplementation is being discussed. The KDIGO guidelines on CKD-MBD (mineral and bone disorders), referenced at the KDIGO guidelines page, provide the evidence framework for managing these complications. For patients managing the supplement side of these questions — understanding which supplements are safe and which are contraindicated — the article on how to review kidney health supplements safely provides a detailed evaluation framework for assessing any supplement claim in the context of CKD. The StatPearls clinical reference on CKD complications and management, at the StatPearls CKD reference, covers the clinical management of anemia, mineral metabolism, and proteinuria in detail.